UCB SA UCBJY
163.20 USD +0.75 (+0.46%)
Nov 12, 2026, 11:10 AM EST
161.62 Day range 163.36
110.55 52-week range 168.76
- YTD
- +16.77%
- 1 year
- +22.63%
News
benzinga.com What's Going On with MoonLake Immunotherapeutics Stock on Thursday? MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.
benzinga.com Medicare Targets 15 High-Profile Drugs In Third Price Negotiation Cycle CMS selects 15 high-cost prescription drugs for Medicare drug price negotiation program, expanding to include Part B drugs.
benzinga.com Johnson & Johnson Touts Encouraging Results For Experimental Lupus Treatment Johnson & Johnson reported encouraging Phase 2 results for its experimental lupus drug nipocalimab in patients with SLE.
benzinga.com J&J Halts Alzheimer's Trial After Drug Fails To Slow Clinical Decline Johnson & Johnson ends its Phase 2b posdinemab trial after missing key Alzheimer's goals, raising concerns for next-generation tau-targeting drug programs.
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021 h2>Upgrades